Vaccine Platform Partnerships Blue Water Biotech owns rights to university developed platforms and is pursuing a universal flu vaccine, plus licensing a norovirus S&P nanoparticle VLP platform to develop vaccines for multiple diseases, creating opportunities for co development, licensing, or contract manufacturing with vaccine developers and global health customers.

Oncology Commercialization Expansion Following the Proteomedix acquisition and the name change to Onconetix, the company is transitioning toward commercial stage oncology assets, presenting sales opportunities with hospital systems, payers, and channel partners for ENTADFI and ZONTIVITY, as well as potential co development of oncology therapies.

Payer and Access Readiness Existing partnerships with Copay Consultants for copay programs, Knipper Health for inventory distribution, and UpScriptHealth for telemedicine support demonstrate a ready to act payer access and patient support infrastructure that can be leveraged to drive adoption of vaccines and oncology assets through payer negotiations, patient assistance programs, and remote care services.

Distribution and Field Readiness The company has a distribution ecosystem with Knipper Health managing inventory and sample distribution and UpScriptHealth enabling telemedicine support for assets like ENTADFI, indicating a field ready setup to support pilots, real world deployment, and provider facing sampling programs.

Growth and Partnerships With modest revenue and significant funding plus strong academic ties to Oxford, CCHMC, and St. Jude, the company presents opportunities for strategic collaborations, licensing deals, and co development programs across vaccines and oncology, including potential equity investments from pharma partners.